Genetics EGAPP Working Group / Agency for Healthcare Quality / AviaraDx Inc. / The EGAPP Working Group / Agency for Healthcare Research / Quest Laboratories / Table 1 Estimated / Genomic Health Inc. / Merck & Co. Inc. / GE / Quest Diagnostics / /
Country
Netherlands / United States / /
Currency
Rs / USD / / /
Event
Product Issues / Reorganization / FDA Phase / /
Facility
Quest Diagnostics/Nichols Institute / University of Utah / ECRI Institute / Science University / Emory University / University of Washington / Agendia’s CLIAcertified laboratory / University of Pennsylvania School / University of California / University of Colorado School / National Cancer Institute / Brown University / Johns Hopkins University / Blue Shield Association Technology Evaluation Center / /
IndustryTerm
low-risk / quality control/quality assessment protocols / intermediate risk / risk / technology assessment / decision-making algorithms / test developers / microarray technology / referent technology / therapy for breast cancer / Treatment of Cancer / diagnostic tools / evidence chain / prevention of breast cancer / preservation solution / conventional risk assessment tools / breast cancer care / clinical management / licensed gene expression profiling technology / mini-array technology / microarray chip / Breast Cancer Treatment / real-time reverse transcription polymerase chain reaction / therapy for early breast cancer / microarray technologies / /
MedicalCondition
early stage ER-positive tumors / direct evidence linking tumor / early-stage invasive breast cancer / significantly less breast cancer / estrogen receptor-positive breast cancer / early breast cancer / tamoxifen-treated / node-negative breast cancer / insufficient tumor / distant metastasis / future metastases / ER-negative tumors / diagnosed early-stage breast cancer / disorder / breast tumor / FFPE tumor / breast cancer / tumor / early-stage breast cancer / locally advanced breast cancer / lymph-node-negative / oestrogen-receptor-positive breast cancer / cancer / distant disease / Tumors / node-negative breast cancer / BACKGROUND AND CLINICAL CONTEXT FOR THE RECOMMENDATION Breast cancer / newly diagnosed breast cancer / distant metastases / ER-positive breast cancer / node negative disease / II breast cancer / breast cancer tumor / metastasis / nausea/vomiting / estrogenreceptor positive breast cancer / MS / HER2-negative tumors / distant breast cancer / common cancer / disease / specific tumor / ER-positive tumors / /
University of Pennsylvania School of Medicine / University of Washington / U.S. Department of Health and Human Services / The Johns Hopkins University / Blue Cross and Blue Shield Association / American Society of Clinical Oncology / Emory University / European Organisation for Research and Treatment of Cancer / University of Utah / Johns Hopkins University Evidence-Based Practice Center / Blue Cross/Blue Shield Association Technology Evaluation Center / University of California / San Francisco / Group of Eight / National Cancer Institute / Warren Alpert Medical School / MammaPrint Service / Washington State Department / National office of Public Health Genomics / Brown University / Johns Hopkins University / Colorado Department of Public Health and Environment / Oregon Health & Science University / Agency for Healthcare Quality and Research / Centers for Disease Control and Prevention / ECRI Institute / Established AHRQ Evidence Based Practice Center / Diagnostics/Nichols Institute / University of Colorado School of Medicine / U.S. Food and Drug Administration / Agency for Healthcare Research and Quality / /
Person
Steven Teutsch / Katrina Armstrong / Ora L. Strickland / Celia Kaye / Joan A. Scott / Kathryn A. Phillips / Maxine Hayes / James Haddow / Alfred O. Berg / Van Vijver / Jeffrey Botkin / Carolyn Sue Richards / Ned Calonge / Margaret Piper / /
EGAPP RECOMMENDATION STATEMENT Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Evaluation of Genomic Applications in Practice and Preven